Search RLYB
Rallybio Corporation
NasdaqCM · CIK 1739410
Last close17.08
Daily change+0.32 (1.91%)
10 Years gain-84.86%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
RLYB · STANDARD
SIC 2834 · Pharmaceutical Preparations · Fiscal year end 1231
Fundamental
30.6Momentum
100.0Acceleration
100.0Confidence
63.0Annual Revenue2
Quarterly Revenue11
Annual CFO6
Balance SheetAvailable
RankingLimited
Score Breakdown
Growth0.0 / 25
Quality15.6 / 25
Capital Efficiency0.0 / 20
Balance Sheet15.0 / 15
Shareholder Economics0.0 / 10
Forward Indicators0.0 / 5
Signals
Operating leverageOperating margin improved by 1008.8443 percentage points.
Net debt reductionNet debt declined versus the comparison period.
Key Metrics
Revenue Growth TTM-25%OK
Revenue CAGR 3Yn/aINSUFFICIENT_HISTORY
Gross Margin100%OK
Operating Margin-4,932.08%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC-4,045.83%OK
Incremental Operating Margin 3Yn/aNOT_MEANINGFUL
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y3.58%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $858,000.00 | $858,000.00 | -$33.06M | -$29.81M | n/a | 100% | -3,853.61% | n/a | n/a | 5.63M |
| 2025 FY Dec 31, 2024 | $636,000.00 | $636,000.00 | -$60.50M | -$49.28M | n/a | 100% | -9,511.95% | n/a | n/a | 5.44M |
| 2024 FY Dec 31, 2023 | n/a | $0.00 | -$78.93M | -$60.27M | -$60.28M | n/a | n/a | n/a | n/a | 40.45M |
| 2023 FY Dec 31, 2022 | n/a | $0.00 | -$67.88M | -$57.28M | -$57.34M | n/a | n/a | n/a | -18,148.35% | 31.82M |
| 2022 FY Dec 31, 2021 | n/a | $0.00 | -$45.65M | -$45.53M | -$45.87M | n/a | n/a | n/a | n/a | 25.52M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $636,000.00 | sum latest 4 fiscal quarters Revenue | OK | 0001628280-26-053880, 0001739410-25-000132 |
| Revenue Growth TTM | -25% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001628280-26-053880, 0001739410-25-000132 |
| Revenue CAGR 3Y | n/a | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | INSUFFICIENT_HISTORY | 0001628280-26-018261 |
| Revenue CAGR 5Y | n/a | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | INSUFFICIENT_HISTORY | 0001628280-26-018261 |
| Gross Profit CAGR 3Y | n/a | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | INSUFFICIENT_HISTORY | 0001628280-26-018261 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001628280-26-053880, 0001739410-25-000132 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 100% | Gross Profit / Revenue | OK | 0001628280-26-053880, 0001739410-25-000132 |
| Operating Margin | -4,932.08% | Operating Income / Revenue | OK | 0001628280-26-053880, 0001739410-25-000132 |
| ROIC | -4,045.83% | NOPAT / Average Invested Capital | OK | 0001628280-26-053880, 0001739410-25-000132 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001628280-26-053880 |
| Current Ratio | 27.26x | Current Assets / Current Liabilities | OK | derived |
| Revenue per Diluted Share | $0.11 | Revenue / Diluted Shares | OK | 0001628280-26-053880, 0001739410-25-000132 |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |